JAK Inhibitors: Prospects in Connective Tissue Diseases

• Published in: Clinical reviews in allergy & immunology Vol. 59; no. 3; pp. 334 - 351
• Main Authors: You, Hanxiao, Xu, Dong, Zhao, Jiuliang, Li, Jing, Wang, Qian, Tian, Xinping, Li, Mengtao, Zeng, Xiaofeng
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2020; Springer; Springer Nature B.V
• Subjects: Allergology; Arthritis; Breast feeding; Clinical trials; Connective tissue diseases; Connective tissues; Corticosteroids; Cytokines; Dermatomyositis; Drug therapy; Immunology; Immunomodulators; Inflammatory diseases; Inhibitor drugs; Internal Medicine; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Rheumatoid arthritis; Rheumatoid factor; Safety; Scleroderma; Scleroderma (Disease); Signal transduction; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma; Systemic sclerosis; Tofacitinib; Vasculitis; DMARDs (biologic); JAK inhibitor; Systemic lupus erythematosus; Rheumatoid arthritis; Systemic sclerosis; Dermatomyositis

The dysregulation of the JAK–STAT pathway is associated with various immune disorders. Four JAK inhibitors have been approved for rheumatoid arthritis (RA), and numerous JAK inhibitors are currently being tested in phase II and III trials for the treatment of various autoimmune inflammatory diseases...